Apixaban

Inkcazelo emfutshane:

Igama le-API Isalathiso Inkcazo USDMF EU DMF CEP
Apixaban VTE Endlwini


Iinkcukacha zeMveliso

Iithegi zeMveliso

IINKCUKACHA ZEMVELISO

Imvelaphi

I-Apixaban yi-inhibitor ekhethiweyo kunye ne-reversible inhibitor ye-Factor Xa enexabiso le-Ki ye-0.08 nM kunye ne-0.17 nM kumntu kunye nomvundla, ngokulandelanayo[1].

I-Factor X, ekwabizwa ngegama elithi Stuart-Prower factor, yi-enzyme ye-coagulation cascade.I-Factor X iyasebenza, nge-hydrolysis, ibe yi-factor Xa zombini i-IX.I-Factor Xa yindlela esetyenzisiweyo ye-coagulation factorthrombokinase.I-Inhibiting Factor Xa inokunika enye indlela ye-anticoagulation.Direct Xa inhibitors zithandwa anticoagulants [2].

I-In vitro: I-Apixabanhas ibonise izinga eliphezulu lamandla, ukukhetha, kunye nokusebenza kakuhle kwi-Factor Xa kunye ne-Ki ye-0.08 nM kunye ne-0.17 nM ye-Human Factor Xa kunye ne-Rabbit Factor Xa, ngokulandelanayo [1].I-Apixaban yandisa amaxesha okuvala i-plasma yomntu eqhelekileyo kunye nokugxininiswa (EC2x) ye-3.6, 0.37, 7.4 kunye ne-0.4 μM, efunekayo ngokulandelanayo ukuphindaphinda ixesha le-prothrombin (PT), ixesha leprothrombin elilungisiweyo (mPT), ixesha elisebenzayo le-thromboplastin ( APTT) kunye neHepTest.Ngaphandle koko, i-Apixaban ibonise amandla aphezulu kwi-plasma yomntu kunye nomvundla, kodwa amandla amancinci kwi-rat kunye ne-dog plasma kuzo zombini ii-PT kunye ne-APTT assays [3].

Kwi-vivo: I-Apixaban ibonise i-pharmacokinetics egqwesileyo enemvume ephantsi kakhulu (Cl: 0.02 L kg-1h-1), kunye nomthamo ophantsi wokusabalalisa (Vdss: 0.2 L / kg) kwinja.Ngaphandle koko, i-Apixaban iphinde yabonisa i-half-life half-life kunye ne-T1 / 2 yeeyure ze-5.8 kunye ne-bioavailability yomlomo omhle (F: 58%) [1].Kwi-arteriovenous-shunt thrombosis (AVST), i-venous thrombosis (VT) kunye ne-carotid arterial thrombosis (ECAT) imodeli yomvundla, i-Apixaban ivelise iziphumo ze-antithrombotic kunye ne-EC50 ye-270 nM, i-110 nM kunye ne-70 nM ngendlela exhomekeke kwi-dose [3]. ].I-Apixaban inhibited kakhulu xa umsebenzi nge-IC50 ye-0.22 μM kumvundla ex vivo[4].Kwi-chimpanzee, i-Apixaban nayo yabonisa umthamo omncinci wokusabalalisa (Vdss: 0.17 L kg-1), imvume ephantsi yenkqubo (Cl: 0.018 L kg-1h-1), kunye ne-bioavailability yomlomo omhle (F: 59%) [5].

IiReferensi:
Pinto DJP, Orwat MJ, Koch S, et al.Ukufunyanwa kwe-1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl) phenyl)-4, 5, 6, 7-tetrahydro-1 H-pyrazolo [3, 4- c] i-pyridine-3-carboxamide (i-Apixaban, i-BMS-562247), i-inhibitor enamandla kakhulu, ekhethiweyo, esebenzayo, kunye ne-oral bioavailable inhibitor ye-blood coagulation factor Xa[J].Ijenali yekhemistri yonyango, i-2007, i-50 (22): 5339-5356.
Sidhu P S. I-Factor Direct Xa Inhibitors njenge-Anticoagulants[J].
Wong PC, Crain EJ, Xin B, et al.I-Apixaban, i-oral, ngokuthe ngqo kunye ne-high selective factor Xa inhibitor: in vitro, antithrombotic kunye ne-antihemostaticstudies[J].Ijenali ye-Thrombosis kunye ne-Haemostasis, i-2008, i-6 (5): 820-829.
Zhang D, He K, Raghavan N, et al.I-Metabolism, i-pharmacokinetics kunye ne-pharmacodynamics ye-factor Xa inhibitor apixaban kwimivundla[J].Ijenali ye-thrombosis kunye ne-thrombolysis, i-2010, i-29 (1): 70-80.
Yena K, uLuettgen JM, uZhang D, et al.I-pharmacokinetics ye-preclinical kunye ne-pharmacodynamics ye-apixaban, into enamandla kunye nekhethiweyo ye-Xa inhibitor[J].Ijenali yaseYurophu ye-metabolism yeziyobisi kunye ne-pharmacokinetics, i-2011, i-36 (3): 129-139.

I-Apixaban yi-inhibitor ekhethiweyo kunye ne-reversible inhibitor ye-Factor Xa enexabiso le-Ki ye-0.08 nM kunye ne-0.17 nM kumntu kunye nomvundla, ngokulandelanayo[1].

I-Factor X, ekwabizwa ngegama elithi Stuart-Prower factor, yi-enzyme ye-coagulation cascade.I-Factor X iyasebenza, nge-hydrolysis, ibe yi-factor Xa zombini i-IX.I-Factor Xa yindlela esetyenzisiweyo ye-coagulation factorthrombokinase.I-Inhibiting Factor Xa inokunika enye indlela ye-anticoagulation.Direct Xa inhibitors zithandwa anticoagulants [2].

I-In vitro: I-Apixabanhas ibonise izinga eliphezulu lamandla, ukukhetha, kunye nokusebenza kakuhle kwi-Factor Xa kunye ne-Ki ye-0.08 nM kunye ne-0.17 nM ye-Human Factor Xa kunye ne-Rabbit Factor Xa, ngokulandelanayo [1].I-Apixaban yandisa amaxesha okuvala i-plasma yomntu eqhelekileyo kunye nokugxininiswa (EC2x) ye-3.6, 0.37, 7.4 kunye ne-0.4 μM, efunekayo ngokulandelanayo ukuphindaphinda ixesha le-prothrombin (PT), ixesha leprothrombin elilungisiweyo (mPT), ixesha elisebenzayo le-thromboplastin ( APTT) kunye neHepTest.Ngaphandle koko, i-Apixaban ibonise amandla aphezulu kwi-plasma yomntu kunye nomvundla, kodwa amandla amancinci kwi-rat kunye ne-dog plasma kuzo zombini ii-PT kunye ne-APTT assays [3].

Kwi-vivo: I-Apixaban ibonise i-pharmacokinetics egqwesileyo enemvume ephantsi kakhulu (Cl: 0.02 L kg-1h-1), kunye nomthamo ophantsi wokusabalalisa (Vdss: 0.2 L / kg) kwinja.Ngaphandle koko, i-Apixaban iphinde yabonisa i-half-life half-life kunye ne-T1 / 2 yeeyure ze-5.8 kunye ne-bioavailability yomlomo omhle (F: 58%) [1].Kwi-arteriovenous-shunt thrombosis (AVST), i-venous thrombosis (VT) kunye ne-carotid arterial thrombosis (ECAT) imodeli yomvundla, i-Apixaban ivelise iziphumo ze-antithrombotic kunye ne-EC50 ye-270 nM, i-110 nM kunye ne-70 nM ngendlela exhomekeke kwi-dose [3]. ].I-Apixaban inhibited kakhulu xa umsebenzi nge-IC50 ye-0.22 μM kumvundla ex vivo[4].Kwi-chimpanzee, i-Apixaban nayo yabonisa umthamo omncinci wokusabalalisa (Vdss: 0.17 L kg-1), imvume ephantsi yenkqubo (Cl: 0.018 L kg-1h-1), kunye ne-bioavailability yomlomo omhle (F: 59%) [5].

IiReferensi:
Pinto DJP, Orwat MJ, Koch S, et al.Ukufunyanwa kwe-1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl) phenyl)-4, 5, 6, 7-tetrahydro-1 H-pyrazolo [3, 4- c] i-pyridine-3-carboxamide (i-Apixaban, i-BMS-562247), i-inhibitor enamandla kakhulu, ekhethiweyo, esebenzayo, kunye ne-oral bioavailable inhibitor ye-blood coagulation factor Xa[J].Ijenali yekhemistri yonyango, i-2007, i-50 (22): 5339-5356.
Sidhu P S. I-Factor Direct Xa Inhibitors njenge-Anticoagulants[J].
Wong PC, Crain EJ, Xin B, et al.I-Apixaban, i-oral, ngokuthe ngqo kunye ne-high selective factor Xa inhibitor: in vitro, antithrombotic kunye ne-antihemostaticstudies[J].Ijenali ye-Thrombosis kunye ne-Haemostasis, i-2008, i-6 (5): 820-829.
Zhang D, He K, Raghavan N, et al.I-Metabolism, i-pharmacokinetics kunye ne-pharmacodynamics ye-factor Xa inhibitor apixaban kwimivundla[J].Ijenali ye-thrombosis kunye ne-thrombolysis, i-2010, i-29 (1): 70-80.
Yena K, uLuettgen JM, uZhang D, et al.I-pharmacokinetics ye-preclinical kunye ne-pharmacodynamics ye-apixaban, into enamandla kunye nekhethiweyo ye-Xa inhibitor[J].Ijenali yaseYurophu ye-metabolism yeziyobisi kunye ne-pharmacokinetics, i-2011, i-36 (3): 129-139.

Ubume beMichiza

Apixaban

ISIQINISEKISO

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

ULAWULO LOMgangatho

Quality management1

Isindululo18Iiprojekthi zoVavanyo loBulunga ezivunyiweyo4, kwaye6iiprojekthi ziphantsi kolwamkelo.

Quality management2

Inkqubo yolawulo lomgangatho wehlabathi ephucukileyo ibeke isiseko esiluqilima sokuthengisa.

Quality management3

Ukongamela umgangatho kutyhutyha umjikelo wobomi bemveliso ukuqinisekisa umgangatho kunye nesiphumo sonyango.

Quality management4

Iqela leMicimbi yoLawulo lobuGcisa lixhasa iimfuno zomgangatho ngexesha lesicelo nokubhaliswa.

ULAWULO LWEMVELISO

cpf5
cpf6

Korea Countec Bottled Packaging Line

cpf7
cpf8

Taiwan CVC Bottled UkuPakisha Line

cpf9
cpf10

Italy CAM Board Packaging Line

cpf11

Umatshini wokuQinisa iFette waseJamani

cpf12

Japan Viswill Tablet Detector

cpf14-1

I-DCS Control Room

UMQHUBA

Intsebenziswano yamazwe ngamazwe
International cooperation
Intsebenziswano yasekhaya
Domestic cooperation

  • Ngaphambili:
  • Okulandelayo:

  • Bhala umyalezo wakho apha kwaye uwuthumele kuthi

    Iindidi zeemveliso